Advances in Label-Free Assays for Antibody Discovery& Development Webinar

1 post / 0 new
jmab728
jmab728's picture
Advances in Label-Free Assays for Antibody Discovery& Development Webinar

Genetic Engineering & Biotechnology News is pleased to announce the following webinar:

Advances in Label-Free Assays for Antibody Discovery, Development, Characterization and Bioprocessing Webinar

Date: Dec. 1, 2010
Time: 9 am PST, 12 pm EST

Register, for free, at www.genengnews.com/labelfree

Label-free assays provide labor-efficient methods for analysis of proteins and peptides during drug development. An established label-free technology, Biolayer Interferometry (BLI), works by continuously monitoring ligand binding on the tip of an optical biosensor, thereby eliminating the need for protein labeling with fluorescent or chromogenic tags.
This method provides multichannel processing of samples using dip and read biosensors, accommodates 96- and 384-well assay formats, simplifies real-time quantitation and kinetic characterization (real-time ka, kd, and affinity) of multiple ligand-ligand interactions, provides crude sample compatibility, and reduces handling steps over traditional technologies such as ELISA, HPLC, and SPR.  Biolayer Interferometry assays have yielded comparable or better resolution and sensitivity to existing bioassay methods and are highly adaptable to analysis of multiple types of biomolecules.
The BLI label-free assays detect low affinity binders often missed by ELISA. Since BLI does not involve microfluidics, these label-free assays allow offline batch immobilization of ligands onto trays of biosensor tips, further streamlining and enabling assay workflows not previously possible.
In this webinar, you will learn how label-free assays embodied in the OCTET platform have been used to optimize therapeutic antibody production and characterization and streamline producer strain identification as well as for the high-throughput analysis of antibody-antigen or protein-protein interactions and, combined with robotics, for unattended analysis of large sets of biotherapeutic candidates.
What Will Be Covered

  • Utility of label-free assays in drug discovery, development, and bioprocessing
  • Protein-protein kinetics, affinity, epitope binning, and mapping
  • Scale-up of antibody quantitation and titer
  • Expression strain screening, cell-line development, and clone selection
  • Downstream process monitoring
  • Low-affinity antibody detection and characterization
  • Low-affinity ADA detection and immunity monitoring
  • Residual protein A and host cell protein contamination detection during antibody purification

 Who Should Attend

  • Protein expression scientists
  • Protein therapeutic development scientists
  • Protein characterization researchers and molecular biologists
  • Analytical method development scientists
  • Protein production QA/QC scientists

 

Panelists Include

  • Yasmina Abdiche, Ph.D., Associate Research Fellow, Rinat-Pfizer
  • Arnout Gerritsen, Ph.D., Associate Director, Assay and BioAnalytical Science, Genmab BV
  • Sriram Kumaraswamy, Ph.D., Senior Product Manager, FortéBio, Inc.

John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News, will be the host of this webinar. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.